MeSH term | MeSH ID | Detail |
---|---|---|
Acute Coronary Syndrome | D054058 | 11 associated lipids |
Airway Remodeling | D056151 | 3 associated lipids |
Acute Kidney Injury | D058186 | 34 associated lipids |
Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.
To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Thromboxane b2
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Tanaka H et al. | Leukotriene (LT)-receptor antagonist is more effective in asthmatic patients with a low baseline ratio of urinary LTE4 to 2,3-dinor-6-keto-prostaglandin (PG)F1alpha. | 1999 | Allergy | pmid:10380781 |
Elissalde MH and Beier RC | Stimulation and release of prostaglandins and thromboxane from macrophages by cotton dust associated lipopolysaccharides. | 1990 | Am Ind Hyg Assoc J | pmid:2270833 |
Andersson T et al. | Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers. | 2012 | Am J Cardiovasc Drugs | pmid:22631032 |
Leese PT et al. | Valdecoxib does not impair platelet function. | 2002 | Am J Emerg Med | pmid:12098171 |
Jung TT and Juhn SK | Prostaglandins in human cholesteatoma and granulation tissue. | 1988 | Am J Otol | pmid:3177602 |
Mehta P et al. | Plasma concentrations of thromboxane and prostacyclin metabolites in patients with bone tumors. | 1985 | Am J Pediatr Hematol Oncol | pmid:2994511 |
Natarajan G et al. | Chorioamnionitis and ontogeny of circulating prostaglandin and thromboxane in preterm infants. | 2008 | Am J Perinatol | pmid:18726836 |
Brown HL et al. | Plasma and amniotic fluid prostacyclin and thromboxane in mild pregnancy-induced hypertension. | 1987 | Am J Perinatol | pmid:3566883 |
Satterfield S et al. | Biochemical markers of compliance in the Physicians' Health Study. | 1990 Sep-Oct | Am J Prev Med | pmid:2268456 |
Ingster LM and Feinleib M | Salicylate intake and cardiovascular disease: Ingster and Feinleib respond to Hu and Willett. | 1998 | Am J Public Health | pmid:9702172 |
Cambria RA et al. | Thromboxane synthetase inhibition decreases polymorphonuclear leukocyte activation following hindlimb ischemia. | 1991 | Am Surg | pmid:1847027 |
Hirsh PD et al. | Influence of blood sampling site and technique on thromboxane concentrations in patients with ischemic heart disease. | 1982 | Am. Heart J. | pmid:7102506 |
Nakashima Y et al. | Sustained-release nifedipine (nifedipine-L) suppresses plasma thromboxane B2 and 6-keto prostaglandin F1 alpha in both young male smokers and nonsmokers. | 1990 | Am. Heart J. | pmid:2353613 |
Buchanan MR et al. | Effect of nafazatrom on platelet function and release: relationship to symptomatic episodes in patients with peripheral vascular disease. | 1987 | Am. Heart J. | pmid:2953219 |
Mehta J and Mehta P | Prostacyclin and thromboxane A2 production by human cardiac atrial tissues. | 1985 | Am. Heart J. | pmid:3880988 |
Friedrich T et al. | Follow-up of prostaglandin plasma levels after acute myocardial infarction. | 1985 | Am. Heart J. | pmid:3880994 |
Zhu BQ and Parmley WW | Modification of experimental and clinical atherosclerosis by dietary fish oil. | 1990 | Am. Heart J. | pmid:2105047 |
Yamada Y et al. | Possible mechanism of vascular reocclusion after initially successful thrombolysis with recombinant tissue-type plasminogen activator. | 1991 | Am. Heart J. | pmid:1903579 |
FitzGerald GA et al. | Cigarette smoking and hemostatic function. | 1988 | Am. Heart J. | pmid:3276116 |
Rebuzzi AG et al. | Importance of reperfusion on thromboxane A2 metabolite excretion after thrombolysis. | 1992 | Am. Heart J. | pmid:1539506 |